ImmunoCellular Therapeutics, Ltd.
IMUC
Price:
$0.138
Market Cap:
$15.63M
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New ...[Read more]
Industry
Biotechnology
IPO Date
2021-01-08
Stock Exchange
PNK
Ticker
IMUC
The ROE as of October 2024 (TTM) for ImmunoCellular Therapeutics, Ltd. (IMUC) is 0%
According to ImmunoCellular Therapeutics, Ltd.’s latest financial reports and current stock price. The company's current ROE is 0%. This represents a change of -100.00% compared to the average of 2.77% of the last 4 quarters.
ImmunoCellular Therapeutics, Ltd. (IMUC) Historical ROE (quarterly & annually)
How has IMUC ROE performed in the past?
The mean historical ROE of ImmunoCellular Therapeutics, Ltd. over the last ten years is -44.34%. The current 0% ROE has changed -100.00% with respect to the historical average. Over the past ten years (40 quarters), IMUC's ROE was at its highest in in the September 2017 quarter at 745.43%. The ROE was at its lowest in in the March 2017 quarter at -1216.77%.
Average
-44.34%
Median
-49.92%
Minimum
-1121.34%
Maximum
1.56%
ImmunoCellular Therapeutics, Ltd. (IMUC) ROE by Quarter and Year
Discovering the peaks and valleys of ImmunoCellular Therapeutics, Ltd. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 541.25%
Maximum Annual ROE = 1.56%
Minimum Annual Increase = -239.30%
Minimum Annual ROE = -1121.34%
| Year | ROE | Change |
|---|---|---|
| 2023 | 28.33% | -55.17% |
| 2022 | 63.19% | -95.95% |
| 2021 | 1.56% | -239.30% |
| 2020 | -1121.34% | 181.51% |
| 2017 | -398.34% | 4.39% |
| 2016 | -381.58% | 541.25% |
| 2015 | -59.51% | 47.56% |
| 2014 | -40.33% | 22.01% |
| 2013 | -33.05% | -47.40% |
| 2012 | -62.84% | -64.49% |
ImmunoCellular Therapeutics, Ltd. (IMUC) Average ROE
How has IMUC ROE performed in the past?
The current ROE of ImmunoCellular Therapeutics, Ltd. (IMUC) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
551.19%
5-year avg
26.78%
10-year avg
-44.34%
ImmunoCellular Therapeutics, Ltd. (IMUC) ROE vs. Peers
How is IMUC’s ROE compared to its peers?
ImmunoCellular Therapeutics, Ltd.’s ROE is less than Northwest Biotherapeutics, Inc. (133.00%), less than Catalyst Pharmaceuticals, Inc. (14.30%), greater than Oxford Cannabinoid Technologies Holdings Plc (-143.95%), greater than Pharming Group N.V. (-6.10%), greater than Kane Biotech Inc. (-64.72%), less than Health Sciences Group, Inc. (0%), less than MedMira Inc. (19.53%), less than Longboard Pharmaceuticals, Inc. (0%), greater than Lumos Pharma, Inc. (-36.93%), greater than Cellectar Biosciences, Inc. (-157.99%), greater than Bolt Biotherapeutics, Inc. (-1855.60%), greater than null (-61.40%),
| Company | ROE | Market cap |
|---|---|---|
| 133.00% | $374.47M | |
| 14.30% | $2.51B | |
| -143.95% | $3.05M | |
| -6.10% | $558.29M | |
| -64.72% | $12.95M | |
| 0% | $187.09K | |
| 19.53% | $36.04M | |
| 0% | $2.31B | |
| -36.93% | $30.71M | |
| -157.99% | $73.85M | |
| -1855.60% | $24.41M | |
| -61.40% | $0 |
Build a custom stock screener for ImmunoCellular Therapeutics, Ltd. (IMUC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ImmunoCellular Therapeutics, Ltd. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
ImmunoCellular Therapeutics, Ltd. (IMUC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like ImmunoCellular Therapeutics, Ltd. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is ImmunoCellular Therapeutics, Ltd.'s ROE?
How is the ROE calculated for ImmunoCellular Therapeutics, Ltd. (IMUC)?
What is the highest ROE for ImmunoCellular Therapeutics, Ltd. (IMUC)?
What is the 3-year average ROE for ImmunoCellular Therapeutics, Ltd. (IMUC)?
What is the 5-year average ROE for ImmunoCellular Therapeutics, Ltd. (IMUC)?
How does the current ROE for ImmunoCellular Therapeutics, Ltd. (IMUC) compare to its historical average?